Search
Sipavibart
go.drugbank.com/drugs/DB21908ApprovedInvestigationalSipavibart is a recombinant human IgG1 monoclonal antibody that is long-acting. … [L53418] Sipavibart gained its first global approval in Japan in December 2024.[A274088] It was later approved in Europe in January 2025 and in Canada in March 2025.
Warfarin
go.drugbank.com/drugs/DB00682ApprovedInvestigationalAlthough originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. … Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration.
Categories: Compounds used in a research, industrial, or household setting, Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic IndexClorazepic acid
go.drugbank.com/drugs/DB00628ApprovedIllicitIn September 2020, a black box warning describing these risks was included on the product label of benzodiazepines as per FDA regulation. … Clorazepic acid (clorazepate) is a water-soluble benzodiazepine with muscle-relaxant and anticonvulsant actions effective in the treatment of anxiety.
International brands: Gen-xeneTestolactone
go.drugbank.com/drugs/DB00894ApprovedWithdrawnAn antineoplastic agent that is a derivative of progesterone and used to treat advanced breast cancer.
Bretylium
go.drugbank.com/drugs/DB01158ApprovedRecent evidence has shown that bretylium may also inhibit the Na,K-ATPase by binding to the extracellular K-site. … Bretylium blocks the release of noradrenaline from the peripheral sympathetic nervous system, and is used in emergency medicine, cardiology, and other specialties for the acute management of ventricular
Synonyms: 2-bromo-N-ethyl-N,N-dimethylbenzenemethanaminium, N-ethyl-N,N-dimethyl-2-bromobenzenemethanaminiumSulindac
go.drugbank.com/drugs/DB00605ApprovedInvestigationalSulindac is a prodrug, derived from sulfinylindene, that is converted _in vivo_ to an active sulfide compound by liver enzymes. … Like other NSAIDs, it may be used in the treatment of acute or chronic inflammatory conditions.
Products: Penta-sulindacKetoconazole
go.drugbank.com/drugs/DB01026ApprovedInvestigationalKetoconazole is an imidazole antifungal agent used in the prevention and treatment of a variety of fungal infections. … [A181802,T116] Ketoconazole was first approved in an oral formulation for systemic use by the FDA in 1981.
Products: Nizoral A-D, A-BE LOTIONAtovaquone
go.drugbank.com/drugs/DB01117ApprovedInvestigationalAtovaquone is a hydroxynaphthoquinone, or an analog of ubiquinone, that has antimicrobial and antipneumocystis activity. It is being used in antimalarial protocols.
Mixtures: ATOVAQUONE E PROGUANILE SANDOZ, ATOVAQUONE E PROGUANILE MYLAN GENERICSProducts: ATOVAQUONE E PROGUANILE SANDOZMilsaperidone
go.drugbank.com/drugs/DB24348ApprovedInvestigationalMilsaperidone is an atypical antipsychotic agent that rapidly interconverts to [iloperidone] in vivo. … [L56056] On February 20, 2026, milsaperidone was approved by the FDA for the treatment of Bipolar I Disorder and schizophrenia.[L56059]
Ravulizumab
go.drugbank.com/drugs/DB11580ApprovedInvestigationalRavulizumab is a potent and selective complement 5 (C5) inhibitor. It is a humanized monoclonal IgG2/4 kappa antibody produced in Chinese hamster ovary (CHO) cells. … [A244465] Ravulizumab was first approved by the FDA on December 21, 2018, for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome in children and adults.